Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 30, 2022 - Issue 7-8
Submit an article Journal homepage
2,648
Views
5
CrossRef citations to date
0
Altmetric
Editorials

Faricimab: Two in the Bush Is Proving Better than One in the Hand?

Ashish Sharmaa Lotus Eye Hospital and Institute, Coimbatore, Tamilnadu, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8550-9791
, MDORCID Icon,
Nilesh Kumara Lotus Eye Hospital and Institute, Coimbatore, Tamilnadu, India
, MD,
Nikulaa Parachuria Lotus Eye Hospital and Institute, Coimbatore, Tamilnadu, India
, MD,
Francesco Bandellob University Vita-Salute, Scientific Institute San Raffaele, Milano, ItalyORCID Iconhttps://orcid.org/0000-0003-3238-9682
, MDORCID Icon,
Baruch D Kuppermannc Gavin Herbert Eye Institute, University of California, Irvine, Irvine, California, USA
, MD &
Anat Loewensteind Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
, MD
Pages 1961-1963 | Received 09 Apr 2021, Accepted 11 May 2021, Published online: 09 Jul 2021

References

  • Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92:713–723. doi:10.1111/aos.12463.
  • Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16:365–374. doi:10.1517/14712598.2016.1131265.
  • Nguyen QD, Heier JS, Do DV, Mirando AC, Pandey NB, Sheng H, Heah T. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int. J. Retina Vitr. 2020;6:48. doi:10.1186/s40942-020-00250-z.
  • Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marmé D, Augustin HG. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem. 2003;278:1721–1727. doi:10.1074/jbc.M208550200.
  • Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Investig. Opthalmol. Vis. Sci. 2008;49:2163. doi:10.1167/iovs.07-1206.
  • Tabruyn SP, Colton K, Morisada T, Fuxe J, Wiegand SJ, Thurston G, Coyle AJ, Connor J, McDonald DM. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am J Pathol. 2010;177:3233–3244. doi:10.2353/ajpath.2010.100059.
  • Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1912–1920.
  • Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood–retinal barrier in diabetic retinopathy. Investig Opthalmol Vis Sci. 2011;52:3784. doi:10.1167/iovs.10-6386.
  • Sharma A, et al. Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefes Arch Clin Exp Ophthalmol. 2021: s00417-021-05164–6. doi:10.1007/s00417-021-05164-6.
  • FDavid AE. First patient dosed in AXT107 clinical trial for DME. https://www.healio.com/news/ophthalmology/20210107/first-patient-dosed-in-axt107-clinical-trial-for-dme.
  • Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye. 2020;34:802–804. doi:10.1038/s41433-019-0670-1.
  • Khanani AM, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964–972. doi:10.1001/jamaophthalmol.2020.2699.
  • A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (TENAYA) - Full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03823287.
  • A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (LUCERNE) - Full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03823300.
  • A study to evaluate the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (YOSEMITE) - Full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03622580.
  • A study to evalu e the efficacy and safety of faricimab (RO6867461) in participants with diabetic macular edema (RHINE). https://clinicaltrials.gov/ct2/show/NCT03622593.
  • New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients. https://www.roche.com/media/releases/med-cor-2021-02-12.htm.
  • Spaide RF. Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization. Am J Ophthalmol. 2015;160:6–16. doi:10.1016/j.ajo.2015.04.012.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.